SCHEDULE: Polaris Funds Boost Camp4 Therapeutics Stake Post-Placement

Polaris Partners and affiliated entities increased their beneficial ownership in Camp4 Therapeutics to 8.4% following a $50.1 million private placement.

Summary

• Polaris Management Co. VII, L.L.C. and its affiliates, along with Polaris Partners GP X, L.L.C. and its affiliates, collectively increased their beneficial ownership in Camp4 Therapeutics Corporation.
• Amir Nashat, a director, now beneficially owns 3,932,251 shares, representing 8.4% of the common stock.
• The increase stems from participation in a private placement where Camp4 Therapeutics raised approximately $50.1 million in an initial closing.
• Polaris Partners VII, L.P. purchased 1,221,721 shares for $1,869,233.13, and Polaris Entrepreneurs' Fund VII, L.P. purchased 85,468 shares for $130,766.04, both at $1.53 per share.
• The private placement involved the sale of 26,681,053 shares of common stock at $1.53 per share and 6,003,758 pre-funded warrants at $1.5299 per warrant.
• Certain members of management, including the CEO, CFO, CMO, and co-founders, also purchased 36,361 shares at $1.65 per share in the initial closing.
• A second closing is contingent on a "Second Closing Trigger," which includes a clinical trial application (CTA) milestone for SYNGAP1-related disorders and either a $7.50 volume-weighted average price threshold or a waiver by majority investors.
• The second closing could raise an additional $50.1 million, with investors purchasing up to 32,721,172 shares/warrants and management purchasing 39,306 shares at $1.65 per share.
• The Issuer entered into a Registration Rights Agreement to register the resale of the purchased shares and warrant shares.

Sentiment

Score: 7

Explanation: The filing indicates a successful capital raise, which is positive for a biotech company's operational runway. The structured second closing tied to a clinical milestone provides a clear path for future funding and de-risking. However, the significant dilution and the ambitious price threshold for the second closing introduce some caution.

Positives

• Successful initial closing of a private placement raising approximately $50.1 million, providing capital for the company.
• Commitment for a potential second closing to raise an additional $50.1 million, contingent on a clinical milestone and share price performance.
• Significant participation from existing institutional investors (Polaris funds) and company management in the capital raise, indicating confidence.
• The CTA Milestone for SYNGAP1-related disorders is a clear development objective.

Negatives

• The private placement involved a substantial issuance of new shares (26,717,414 shares in the initial closing alone), leading to significant dilution for existing shareholders.
• The share price for the private placement ($1.53 per share) is a key data point for valuation.
• The second closing is contingent on specific milestones and a potentially high price threshold ($7.50 VWAP), which may not be met.

Risks

• Dilution Risk: The private placement, particularly with the potential second closing, involves substantial issuance of new shares, which will dilute the ownership percentage of existing shareholders.
• Clinical Trial Risk: The second closing is contingent on achieving a CTA Milestone for SYNGAP1-related disorders, which is subject to regulatory approval and the inherent uncertainties of drug development.
• Market Price Risk: The second closing is also contingent on the company's stock achieving a volume-weighted average price of $7.50 or greater, which is significantly higher than the private placement price and may not be realized.
• Execution Risk: The successful completion of the second closing and the full capital raise depends on the company's ability to meet the specified conditions.

Future Outlook

The company anticipates a second closing of the private placement, which is contingent upon achieving a clinical trial application (CTA) milestone for its SYNGAP1-related disorders development candidate and either a $7.50 volume-weighted average price threshold or a waiver from majority investors. This second closing could provide an additional $50.1 million in gross proceeds.

Management Comments

• The Issuer's CEO Josh Mandel-Brehm, CFO Kelly Gold, CMO Yuri Maricich, and co-founders Richard Young and Leonard Zon participated in the private placement, purchasing shares at $1.65 per share.

Industry Context

This capital raise is typical for a biotechnology company like Camp4 Therapeutics, which requires significant funding to advance its drug development pipeline. Private placements are a common method for early to mid-stage biotech firms to secure capital from institutional investors, often with structured tranches tied to development milestones. The focus on SYNGAP1-related disorders indicates a commitment to rare neurological diseases, an area with high unmet medical need but also high development risk.

Comparison to Industry Standards

• The structure of the private placement, with an initial closing and a contingent second closing tied to a clinical milestone (CTA) and a share price threshold, is a common financing mechanism in the biotech industry. This allows investors to de-risk their investment by tying further capital deployment to scientific and market progress.
• The participation of existing institutional investors like Polaris Partners, who also have board representation (Amir Nashat), is standard for venture-backed biotech companies, providing both capital and strategic guidance.
• The share price of $1.53 for the private placement, compared to the $7.50 price threshold for the second closing, suggests a significant expected appreciation in value upon achieving the CTA milestone, which is a common incentive structure in such deals.

Related Party Transactions

• Amir Nashat, a member of the Issuer's board of directors, is associated with the Polaris funds that participated in the private placement and beneficially owns 8.4% of the company's common stock.
• The Issuer's CEO Josh Mandel-Brehm, CFO Kelly Gold, CMO Yuri Maricich, co-founder and director Richard Young, and co-founder and board observer Leonard Zon participated in the private placement, purchasing shares at $1.65 per share.

Stakeholder Impact

• Shareholders: Existing shareholders face significant dilution due to the issuance of new shares in the private placement. However, the capital raise provides funding for company operations and development, potentially increasing long-term value.
• Investors (Polaris Funds): Increased stake and potential for further investment upon milestone achievement, with registration rights for resale.
• Management: Increased personal investment in the company, aligning interests with shareholders.
• Creditors: Improved financial stability due to increased cash reserves from the capital raise.

Next Steps

• Achieve the CTA Milestone for the SYNGAP1-related disorders development candidate.
• Monitor the volume-weighted average price of the common stock to meet the $7.50 threshold for the second closing, or secure a waiver from majority investors.
• Complete the second closing of the private placement, if triggered.
• Prepare and file to register for resale the shares of Common Stock and Warrant Shares issued in the private placement, as per the Registration Rights Agreement.

Key Dates

Recommendation

While the capital raise provides essential funding and management/institutional investor participation shows confidence, the significant dilution from the private placement and the contingent nature of the second tranche introduce uncertainty. The stock's ability to reach the $7.50 price threshold for the second closing is a substantial hurdle. Investors should hold to observe progress on the CTA milestone and the company's ability to execute on its development pipeline, which will be key drivers for future valuation.

Keywords

Camp4 Therapeutics, Polaris Partners, Schedule 13D/A, Private Placement, Capital Raise, Biotechnology, SYNGAP1, Clinical Trial, Share Dilution, Institutional Investment, SEC Filing